Treatment of osteoporosis in men

Journal of Men's Health and Gender

Volumn 4, Issue 3, 2007, Pages 326-333

  Ringe, Johann D ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bone mineral density; Fractures; Men; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; FLUORIDE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; VITAMIN D;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; EUROPEAN UNION; FRACTURE; HUMAN; IDIOPATHIC OSTEOPOROSIS; LOW DRUG DOSE; LUMBAR SPINE; MEN'S HEALTH; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; SUPPLEMENTATION;

EID: 34548202670     PISSN: 15718913     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhg.2006.11.003     Document Type: Article

References (37)

1. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med 98 2A (1995) 3S-8S
2. Campion J.M., and Maricic M.J. Osteoporosis in men. Am Fam Physician 67 7 (2003) 1521-1526
3. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 9156 (1999) 878-882
4. Olszynski W.P. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26 1 (2004) 15-28
5. Ringe J.D. Osteoporosis in men. In: Hosking D., and Ringe J. (Eds). Treatment of Metabolic Bone Disease. Management Strategy and Drug Therapy (2000), Martin Dunitz, London
6. Kiebzak G.M., Beinart G.A., Perser K., Ambrose C.G., Siff S.J., and Heggeness M.H. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162 19 (2002) 2217-2222
7. Nguyen T.V., Center J.R., and Eisman J.A. Osteoporosis: underrated, under-diagnosed and undertreated. Med J Aust 180 5 Suppl (2004) S18-S22
8. Amin S., and Felson D.T. Osteoporosis in men. Osteoporos Int 27 (2001) 19-47
9. Orwoll E., and Klein R. Osteoporosis in Men. 2nd edn. (2001), Academic Press, San Diego
10. Ringe J.D., Dorst A.J., and Faber H. Osteoporosis in men - clinical assessment of 400 patients and 205 controls by risk factor analysis, densitometry, and x-ray findings. Osteologie 6 (1997) 81-86
11. Pietschmann F., Breslau N.A., and Pak C.Y.C. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 7 (1992) 1383-1388
12. Donaldson L.J., Cook A., and Thomson R.G. Incidence of fractures in a geographically defined population. J Epidemiol Comm Health 44 (1990) 241-245
13. Group E.P.O.S. Incidence of vertebral fracture in Europe: Results from the European prospective osteoporosis study (EPOS). J Bone Miner Res 17 (2002) 716-724
14. Ringe J.D. Osteoporose des Mannes. Dtsch med Wschr 128 (2003) 925-928
15. Finkelstein J.S., Klibanski A., Neer R.M., Doppelt S.H., Rosenthal D.I., Segre G.V., et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 69 (1989) 776-783
16. Snyder P.J., Peachey H., Berlin J.A., Hannoush P., Haddad G., Dlewati A., et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85 8 (2000) 2670-2677
17. Wang C., Swerdloff R.S., Iranmanes A., Dobs A., Snyder P.J., Cunnigham G., et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol 54 (2001) 739-750
18. Habib G.S., and Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticoids. Clin Rheumatol 24 (2005) 129-133
19. Trovas G.P., Lyritis G.P., Galanos A., Raptou P., and Constantelou E. A randomised trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17 (2002) 521-527
20. Ringe J.D., Dorst A., Kipshoven C., Rovati L.C., and Setnikar I. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporosis Int 8 (1998) 47-52
21. Andersen F.H., Francis R.M., Bishop D.J., and Rawlings D. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. Age Ageing 156 (1997) 359-365
22. Geusens P., Vanhoof J., Raus J., Dequeker J., Nijs J., and Joly J. Treatment with etidronate for men with idiopathic osteoporosis. Ann Rheum Dis 56 (1997) 280
23. Ringe J.D., Orwoll E., Daifotis A., and Lombardi A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13 (2002) 195-199
24. Orwoll E., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 9 (2000) 604-610
25. Ringe J.D., Dorst A., Faber H., and Ibach K. Alendonate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatology Int 24 (2004) 110-113
26. Miller P., Schnitzer T., Emkey R., Orwoll E., Rosen C., Ettinger M., et al. Weekly alendronate acid in male osteoporosis. Clin Drug Investig 24 (2004) 333-341
27. Roux C., Seeman E., Eastell R., Adachi J., Jackson R.D., Felsenberg D., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20 4 (2004) 433-439
28. Harrington T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., et al. Risedronate rapidly reduces the risk for non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74 (2004) 129-135
29. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
30. Reid D.M., Adami S., Devogelaer J.P., and Chines A.A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69 (2001) 242-247
31. Ringe J.D., Faber H., Farahmand P., and Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis. Results of a 1-year study. Rheumatol Int 26 (2006) 427-431
32. Boonen S., Delmas P.D., Wenderoth D., Stoner K.J., Eusebio R., and Orwoll E.S. Risedronate shown to be safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicenter study. Osteoporos Int 17 Suppl 2 (2006) S230-S231
33. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., and Bilezikian J.P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on mineral density and bone markers. J Clin Endocrinol Metab 85 (2000) 3069-3076
34. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
35. Kaufman J.M., Scheele W.H., Orwoll E., Clancy A.D., Adami S., Syversen U., et al. Recombinant human parathyroid hormone (1-34) therapy increases bone mineral density and may decrease the risk of fractures in men with low bone density. Osteoporos Int 12 Suppl. 2 (2001) S13
36. Orwoll E., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men osteoporosis. J Bone Miner Res 18 1 (2003) 9-17
37. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468